Your support of Gabrielle’s Angel Foundation allows us to push the boundaries of what is scientifically possible for those living with blood cancer. Meet the dedicated research scientists whose cutting-edge ideas are giving patients reason to hope and hear all about their latest breakthroughs below!
Former Gabrielle’s Angel Foundation Grantee Dr. Ross Levine has been named the Chief Scientific Officer of Memorial Sloan Kettering Cancer Center. We first funded Dr. Levine with a Medical...
We are thrilled to share that Dr. Anthony Letai, a 2007 Gabrielle’s Angel Foundation grantee, has been appointed Director of the National Cancer Institute. We supported Dr. Letai early in his...
Omar Abdel-Wahab, MD, Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI); Evnin Family Chair in Molecular Pharmacology and Attending Physician on the Leukemia Service at...
We are proud to announce that Gabrielle’s Angel Foundation’s Medical Advisory Board recently approved the funding for 8 new grants of $225,000 each, totaling $1.8 million! We are...
A recently published article in Newsweek discusses the groundbreaking advancements in genetic sequencing that are transforming cancer treatment. It highlights how technologies like whole genome...
Marco Ruella, MD, Gabrielle’s Angels grantee in 2014 and 2017 (Medical Advisory Board discretionary funding) and 2019 (Medical Research Award), assistant professor, medicine...
Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug...
Gabrielle’s Angel Foundation grantee Grant Challen, PhD (MRA recipient in 2016 and The Mark Foundation for Cancer Research Collaborative Grant Recipient from 2023) from Washington University in...
Big news from Dana-Farber Cancer Institute regarding the FDA approval of revumenib for the treatment of relapsed acute leukemia! Gabrielle’s Angel Foundation funded Scott Armstrong, MD, PhD...
After an allogeneic stem cell transplant, a recipient’s body faces a daunting task: rebuilding the person’s blood-forming and immune systems from the ground up from a relatively small number of...
Exciting news out of Dana-Farber on a the development of new menin-targeting agents that showed promise in clinical trials involving adults with acute myeloid leukemia (AML), one of the...
With your support in 2023, we were able to fund 6 new individual researchers with grants of $225,000 each as well as co-funding with The Mark Foundation for Cancer Research 2 new collaborative...